Cargando…

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

BACKGROUND: Elevated B lymphocyte stimulator (BLyS) levels in patients with systemic lupus erythematosus (SLE) correlate positively with disease activity; BLyS expression is directly linked to interferon (IFN) pathway activation. This post hoc meta-analysis of BLISS-52 and BLISS-76 explored the rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkinson, Christel, Henderson, Robert B., Jones-Leone, Angela R., Flint, Shaun M., Lennon, Mark, Levy, Roger A., Ji, Beulah, Bass, Damon L., Roth, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197114/ https://www.ncbi.nlm.nih.gov/pubmed/32366280 http://dx.doi.org/10.1186/s13075-020-02177-0

Ejemplares similares

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
por: Collins, Christopher E, et al.
Publicado: (2006)

Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B
Publicado: (2012)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019)

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)
por: Stohl, William
Publicado: (2010)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
por: Stohl, William
Publicado: (2003)

The current status of targeting BAFF/BLyS for autoimmune diseases
por: Ramanujam, Meera, et al.
Publicado: (2004)

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
por: Furie, Richard, et al.
Publicado: (2008)

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
por: López, Patricia, et al.
Publicado: (2016)

G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
por: Scapini, Patrizia, et al.
Publicado: (2003)

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin
por: Parameswaran, Reshmi, et al.
Publicado: (2012)

Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
por: Maslen, Toni, et al.
Publicado: (2021)

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells
por: Zhu, Jing, et al.
Publicado: (2012)

Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Human BLyS Facilitates Engraftment of Human PBL Derived B Cells in Immunodeficient Mice
por: Schmidt, Madelyn R., et al.
Publicado: (2008)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Roles for BLyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells
por: Sindhava, Vishal J., et al.
Publicado: (2013)

B Lymphocyte Stimulator (BLyS) Is Expressed in Human Adipocytes In Vivo and Is Related to Obesity but Not to Insulin Resistance
por: Müller, Nike, et al.
Publicado: (2014)

Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo
por: Luster, Troy A., et al.
Publicado: (2012)

Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2014)

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation
por: Goenka, Radhika, et al.
Publicado: (2014)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
por: Cai, Shaozhe, et al.
Publicado: (2023)

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2022)

Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS)
por: Gor, Dennis O, et al.
Publicado: (2011)

High Expression Levels of BLyS/BAFF by Blood Dendritic Cells and Granulocytes Are Associated with B-cell dysregulation in SIV-Infected Rhesus Macaques
por: Poudrier, Johanne, et al.
Publicado: (2015)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
por: Ginzler, Ellen, et al.
Publicado: (2021)

Blood B Lymphocyte Stimulator (BLyS)/BAFF levels may reflect natural immunity to HIV in highly exposed uninfected Beninese Commercial Sex Workers
por: Sabourin-Poirier, Catherine, et al.
Publicado: (2016)

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
por: Brunner, Hermine I, et al.
Publicado: (2020)

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
por: Zhang, Fengchun, et al.
Publicado: (2018)

Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores
por: van den Hoogen, Lucas L, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fh6mh64rq18itf4oi7ndfht1fo